文献速递细菌感染、耐药与抗菌药物

头孢洛林对高MIC金黄色葡萄球菌的体外中空纤维模型疗效

Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

本研究用体外中空纤维感染模型评估头孢洛林对12株头孢洛林MIC为2或4 mg/L的临床MRSA分离株的PK/PD,q8h给药24小时。结果显示平均抑菌、1 log10杀菌和2 log10杀菌PK/PD靶值分别为29%、32%和35% fT>MIC;600 mg q8h模拟给药对MIC 2和4 mg/L菌株实现持续长期细菌抑制。结论提示600 mg头孢洛林磷酯q8h对MIC≤4 mg/L的金黄色葡萄球菌有效。

要点

  • 头孢洛林600 mg q8h对MIC 2和4 mg/L的MRSA分离株在HFIM中显示持续抑菌。
  • MRSA的PK/PD靶值不受常见非PBD替换影响。
  • 平均抑菌、1 log10和2 log10杀菌靶值分别为29%、32%和35% fT>MIC。

核心结论

  • 体外HFIM显示600 mg头孢洛林磷酯q8h对头孢洛林MIC≤4 mg/L的金黄色葡萄球菌有效。

研究设计与样本

  • 研究采用体外中空纤维感染模型(HFIM),评估头孢洛林对12株头孢洛林MIC为2或4 mg/L的临床MRSA分离株的PK/PD,q8h给药24小时。
  • 另评估头孢洛林MIC 2至32 mg/L的突变株对600 mg q8h人体模拟剂量72小时的PD反应。

主要发现

  • 平均抑菌、1 log10杀菌和2 log10杀菌PK/PD靶值分别为29%、32%和35% fT>MIC。
  • 数据提示MRSA的PK/PD靶值不受MIC≤2 mg/L分离株中常见非PBD替换的影响。
  • 600 mg q8h给药在HFIM中对头孢洛林MIC 2和4 mg/L的分离株显示持续长期细菌抑制。

关键数值与推荐

  • 当前CLSI和EUCAST对头孢洛林600 mg q12h治疗金黄色葡萄球菌的临床敏感折点为≤1 mg/L。
  • 头孢洛林MIC≥2 mg/L的金黄色葡萄球菌感染疗效数据有限。

临床怎么用

  • 对于头孢洛林MIC≤4 mg/L的金黄色葡萄球菌,600 mg q8h给药方案在HFIM中显示有效,可支持临床用药选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The current CLSI and EUCAST clinical susceptible breakpoint for 600 mg q12h dosing of ceftaroline (active metabolite of ceftaroline fosamil) for Staphylococcus aureus is ≤1 mg/L. Efficacy data for S. aureus infections with ceftaroline MIC ≥2 mg/L are limited. This study was designed to generate in-depth pharmacokinetic/pharmacodynamics (PK/PD) understanding of S. aureus isolates inhibited by ≥ 2 mg/L ceftaroline using an in vitro hollow-fibre infection model (HFIM). METHODS: The PK/PD target of ceftaroline was investigated against 12 diverse characterized clinical MRSA isolates with ceftaroline MICs of 2 or 4 mg/L using q8h dosing for 24 h. These isolates carried substitutions in the penicillin-binding domain (PBD) and/or the non-PBD. Additionally, PD responses of mutants with ceftaroline MICs ranging from 2 to 32 mg/L were evaluated against the mean 600 mg q8h human-simulated dose over 72 h. RESULTS: The mean stasis, 1 log10-kill and 2 log10-kill PK/PD targets were 29%, 32% and 35% f T>MIC, respectively. In addition, these data suggest that the PK/PD target for MRSA is not impacted by the presence of substitutions in the non-PBD commonly found in isolates with ceftaroline MIC values of ≤ 2 mg/L. HFIM studies with 600 mg q8h dosing demonstrated a sustained long-term bacterial suppression for isolates with ceftaroline MICs of 2 and 4 mg/L. CONCLUSIONS: Overall, efficacy was demonstrated against a diverse collection of clinical isolates using HFIM indicating the utility of 600 mg ceftaroline fosamil for S. aureus isolates with MIC ≤4 mg/L using q8h dosing.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Singh R, Almutairi M, Alm RA, et al. Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model. J Antimicrob Chemother. 2017. PMID: 29091195. doi:10.1093/jac/dkx214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。